Abstract: We found that the mutations K101A, P225H, Y318F and Y318W decreased RT heterodimer stability whereas K103N, V108I, V108W, Y181C, Y188L, G190A, G190E, G190W and P225W increased RT heterodimer stability.
Development of Novel Dihydrofuro[3,4-d]pyrimidine Derivatives as HIV-1 NNRTIs to Overcome the Highly Resistant Mutant Strains F227L/V106A and K103N/Y181C.
Abstract: A three-layered ONIOM model was used to study the interactions between efavirenz and the binding sites of HIV-1 reverse transcriptase (RT): wild-type and double mutant K103N/Y181C enzyme forms.
Abstract: The calculated binding energy for the efavirenz-K103N/Y181C HIV-1 RT complex is less than that with the wild-type complex by approximately 8 kcal mol(-1).
Abstract: The interaction energies, calculated at the MP2/6-31G(d,p) level between efavirenz and individual residues surrounding the binding pocket of the K103N/Y181C enzyme, demonstrate that the attractive interactions between efavirenz and residue positions 101 and 103 were less than those for wild-type <
Prevalence of resistance mutations in HIV-1-Infected Hondurans at the beginning of the National Antiretroviral Therapy Program.
PMID: 18366313
2008
AIDS research and human retroviruses
Abstract: K103N mutations were present in 3.0% of study specimens.
Development of Novel Dihydrofuro[3,4-d]pyrimidine Derivatives as HIV-1 NNRTIs to Overcome the Highly Resistant Mutant Strains F227L/V106A and K103N/Y181C.
PMID: 18370589
2008
AIDS research and human retroviruses
Abstract: A cutoff of 0.5% K103N for detection of K103N was used for both assays.
Abstract: Forty-six samples (73.0%) were positive for K103N by both assays and 13 samples (20.6%) were negative by both assays.
Abstract: Results for the percentage K103N were similar for the two assays (R(2) = 0.92).
Abstract: The percentage K103N determined by clonal analysis was consistent with the LigAmp result for five of eight samples, and was consistent with the ASPCR result for three of eight samples.
Abstract: The percentage K103N was also determined by analyzing 40 HIV clones from each of these eight samples, using a combined amplification/sequencing method (AmpliSeq).
Abstract: We compared the ability of the LigAmp assay and an ASPCR assay to detect and qua
Low rate of emergence of nevirapine and lamivudine resistance after post-partum interruption of a triple-drug regimen.
Abstract: Analysis of K103N by SPCR showed that 35% of the patients contained < or =0.1% of viruses carrying either the AAC or AAT mutations.
Abstract: Sequence-selective real-time PCR (SPCR), which quantifies minority viral populations containing K103N, Y181C and M184V mutations, and standard genotypic sequencing were assayed.
Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa.
Abstract: Interestingly, one compound showed dissociation rates from the ternary complex with RT mutants K103N and Y181I 10-20-fold slower than from the corresponding complex with wild-type RT.
Abstract: These compounds are highly active against both wild-type HIV-1 and the K103N, Y181C, and Y188L mutant strains.
Profile of drug resistance mutations among HIV-1-infected Tunisian subjects failing antiretroviral therapy.
Abstract: In the RT gene, resistance to nucleoside RT inhibitors (NRTIs) and non-nucleoside RT inhibitors (NNRTIs) were recognized in 66.25 and 37.5%, respectively, with M184V, T215Y and K103N being the codons most frequently involved.
"Selective targeting of the HIV-1 reverse transcriptase catalytic complex through interaction with the ""primer grip"" region by pyrrolobenzoxazepinone non-nucleoside inhibitors correlates with increased activity towards drug-resistant mutants."
Abstract: Our kinetic analysis indicates that the ability of PBOs to selectively target the catalytic ternary complex of RT with its substrates directly correlates with greatly reduced sensitivity to NNRTIs-resistance mutations, particularly the K103N substitution.
HIV mutation literature information.
PMID: 
2008
Current HIV research
Browser Board
Co-occurred Entities
Filtrator
ViMRT